Researchers have launched a promising phase II/III clinical trial, known as the MODERN study, to explore whether a simple blood test could transform how doctors manage urothelial cancer after surgery. The trial focuses on patients who have had their bladder, kidney, ureter, or urethra surgically removed due to urothelial cancer and examines whether measuring circulating tumor DNA (ctDNA) in the bloodstream can help identify who truly needs additional immunotherapy treatment.
Circulating tumor DNA refers to tiny fragments of genetic material that cancer cells release into the blood. Because this DNA can sometimes be detected before changes appear on imaging scans, it offers an exciting opportunity for earlier and more precise decision-making. In this trial, doctors will use ctDNA levels to help determine which patients may still have cancer cells present in their body after surgery — and therefore might benefit most from further treatment.
The study will evaluate two forms of immunotherapy: nivolumab, a monoclonal antibody already used in cancer treatment to help the immune system recognize and attack tumor cells, and relatlimab, another monoclonal antibody being studied for its potential to enhance the immune response even further when combined with nivolumab. By comparing outcomes among patients guided by ctDNA testing, researchers hope to learn whether this blood-based approach can help extend the time patients remain free of disease progression and potentially prolong survival.
What makes this trial especially encouraging is its potential to move cancer care toward more personalized, data-driven treatment decisions. Rather than giving immunotherapy to all post-surgical patients uniformly, ctDNA testing could allow doctors to focus treatment on those most likely to benefit, potentially sparing others from unnecessary therapy and its associated burdens. This kind of precision approach reflects a broader trend in oncology toward using biological markers to tailor treatment plans to each patient’s unique situation.
If successful, the MODERN study could pave the way for wider adoption of ctDNA testing as a standard tool in cancer monitoring, not just for urothelial cancers but potentially for other tumor types as well. Trials like this represent meaningful steps forward in improving outcomes and quality of life for cancer patients through smarter, more targeted care strategies.
This article is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply